4 recruiting, 3 not yet recruiting, 1 completed, 1 unknown. 5 Phase 2, 4 Phase 1, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 2, Completed 1, Not yet recruiting 1, Unknown 1 |
| Phase 1 | 4 | Completed 1, Not yet recruiting 1, Recruiting 1, Unknown 1 |
| Early Phase 1 | 1 | Recruiting 1 |
Follow Non-Hodgkin Lymphoma, B-cell: new trials by email Literature Review of Non-Hodgkin Lymphoma, B-cell trials Research Report on Non-Hodgkin Lymphoma, B-cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma BAFF CAR-T - Non-Hodgkin Lymphoma Refractory/ Relapsed, Multiple Myeloma Refractory | Phase 2 | Not yet recruiting | Luminary Therapeutics | 90 | 2026-12-01 | 2026-08-18 |
| An Extension Study to Evaluate the Safety and Efficacy of an Anti-CD19 CAR-T Product in Patients with B-cell Lymphoproliferative Disorders Non-Hodgkin Lymphoma, B-cell, Acute Lymphoblastic Leukemia ALL | Not yet recruiting | National Research Center for Hematology, Russia | 60 | 2025-01-09 | 2024-12-06 | |
| MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01) MEN1703, Glofitamab - Non-Hodgkin Lymphoma, B-cell | Phase 2 | Recruiting | Ryvu Therapeutics SA | 178 | 2024-12-05 | 2026-09-18 |
| A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders Hem101 - Non-Hodgkin Lymphoma, B-cell, Acute Lymphoblastic Leukemia ALL | Phase 1 / Phase 2 | Completed | National Research Center for Hematology, Russia | 58 | 2024-11-26 | 2026-02-09 |
| Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). CD19/CD22-CAR T cells - Acute Lymphoblastic Leukemia, Adult B-Cell, Acute Lymphoblastic Leukemia, in Relapse | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 75 | 2024-07-10 | 2025-08-06 |
| A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL) CD19/CD20/BCMA CAR T cells - Non-Hodgkin Lymphoma, B-cell | Early Phase 1 | Recruiting | Shanghai Cell Therapy Group Co.,Ltd | 20 | 2024-05-07 | 2025-08-21 |
| A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma SCTB35 injection - Non-Hodgkin Lymphoma, B-cell | Phase 1 | Not yet recruiting | Sinocelltech Ltd. | 76 | 2024-04-01 | 2024-03-22 |
| A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice "novel" MAB (alone or in combination) - Non-Hodgkin Lymphoma, B-cell | Recruiting | Fondazione Italiana Linfomi - ETS | 1500 | 2023-12-27 | 2025-12-29 | |
| T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies CD19 CAR T cells - Acute Lymphoblastic Leukemia, B-precursor, Non-Hodgkin Lymphoma, B-cell | Phase 1 / Phase 2 | Unknown | Sheba Medical Center | 300 | 2016-11-01 | 2020-11-03 |
Lymphoma, Non-Hodgkin (9) · Lymphoma, B-Cell (5) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Recurrence (2) · Aggression (1) · Lymphoma (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Multiple Myeloma (1) · Neoplasms (1)
Hemic and Lymphatic Diseases (9) · Immune System Diseases (9) · Immunoproliferative Disorders (9) · Lymphatic Diseases (9) · Lymphoproliferative Disorders (9) · Neoplasms by Histologic Type (9) · Lymphoma (8) · Neoplasms (8) · Hematologic Diseases (5) · Leukemia (4) · Leukemia, Lymphoid (4) · Disease Attributes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Aberrant Motor Behavior in Dementia (1)
Single Person (1) · glofitamab (1)
National Research Center for Hematology, Russia (2) · Essen Biotech (1) · Fondazione Italiana Linfomi - ETS (1) · Luminary Therapeutics (1) · Ryvu Therapeutics SA (1) · Shanghai Cell Therapy Group Co.,Ltd (1) · Sheba Medical Center (1) · Sinocelltech Ltd. (1)
China (3) · Russia (2) · France (1) · Israel (1) · Italy (1) · Poland (1) · Spain (1) · United Kingdom (1)
Jinxing Lou (1) · Marco Ladetto, Prof. (1) · Yuqin Song, M.D. (1)